💥Fed cuts sparks mid cap boom! ProPicks AI scores with 4 stocks +23% each. Get October’s update first.Pick Stocks with AI

U.S. man with transplanted genetically modified pig heart dies

Published 03/09/2022, 10:21 AM
Updated 03/09/2022, 11:01 PM
© Reuters. Surgeon Muhammad M. Mohiuddin, MD leads a team placing a genetically-modified pig heart into a storage device at the Xenotransplant lab before its transplant on David Bennett, a 57-year-old patient with terminal heart disease, at University of Maryland Medical Center in Baltimore, Maryland, U.S. January 7, 2022. Picture taken January 7, 2022.  University of Maryland School of Medicine (UMSOM)/Handout via REUTERS.

By Kanishka Singh

(Reuters) - A 57-year-old man with terminal heart disease who made history as the first person to receive a genetically modified pig's heart died on Tuesday at the University of Maryland Medical Center (UMMC), the hospital said.

David Bennett received the transplant on Jan 7.

His condition began deteriorating several days ago, the hospital said in a statement on Wednesday, and he was given "compassionate palliative care" after it became clear that he would not recover.

Bennett "wasn't able to overcome what turned out to be the devastating debilitation" caused by the heart failure he experienced before the transplant, Dr. Bartley Griffith, director of the UMCC cardiac transplant program, said in a videotaped statement.

The transplanted heart functioned "beautifully," Griffith said.

Bennett was able to communicate with his family during his final hours, the hospital said.

Bennett first came to UMMC as a patient in October and was placed on a heart-lung bypass machine, but was deemed ineligible for a conventional heart transplant.

After Bennett received a pig heart that had been modified to prevent rejection with the use of new gene editing tools, his son called the procedure "a miracle."

For Bennett, the procedure was his last option.

"Before consenting to receive the transplant, Mr Bennett was fully informed of the procedure's risks, and that the procedure was experimental with unknown risks and benefits," the hospital said.

© Reuters. Surgeon Muhammad M. Mohiuddin, MD leads a team placing a genetically-modified pig heart into a storage device at the Xenotransplant lab before its transplant on David Bennett, a 57-year-old patient with terminal heart disease, at University of Maryland Medical Center in Baltimore, Maryland, U.S. January 7, 2022. Picture taken January 7, 2022.  University of Maryland School of Medicine (UMSOM)/Handout via REUTERS.

Researchers have long considered pigs to be a potential source of organs for transplants because they are anatomically similar to humans in many ways. Prior efforts at pig-to-human transplants had failed because of genetic differences that caused organ rejection or viruses that posed an infection risk.

"The demonstration that it was possible - that we were able to take a genetically engineered organ and watch it function flawlessly for nine weeks, is pretty positive in terms of the potential for this therapy," Griffith said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.